The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARα

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6080-6088

  Puccetti, Elena ^a,d   Zheng, Xiaomin ^a   Brambilla, Daria ^b   Seshire, Anita ^a   Beissert, Tim ^a   Boehrer, Simone ^a   Nürnberger, Heike ^a   Hoelzer, Dieter ^a   Ottmann, Oliver Gerhard ^a   Nervi, Clara ^b,c   Ruthardt, Martin ^a,d  

^a GOETHE UNIVERSITY   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c San Raffaele Biomedical Science Foundation of Rome   (Italy)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HYBRID PROTEIN; RETINOIC ACID RECEPTOR ALPHA; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; FEMALE; LEUKEMOGENESIS; LYMPHOCYTE DIFFERENTIATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

ACUTE DISEASE; ANIMALS; COS CELLS; DIMERIZATION; FEMALE; HEMATOPOIETIC STEM CELLS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; MUTAGENESIS, SITE-DIRECTED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; ZINC FINGERS;

EID: 22244433500     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3631     Document Type: Article

References (25)

1. Zheng X Beissert T, Kukoc-Zivojnov N, et al. γ-Catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004;103:3535-43.
2. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
3. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia 2004;18:1169-75.
4. Grignani F, Gelmetti V, Fanelli M, et al. Formation of PML/RARα high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RARα-mediated retinoic acid response. Oncogene 1999;18:6313-21.
5. Grignani F, Pelicci PG. Pathogenetic role of the PML1RARα fusion protein in acute promyelocytic leukemia. Curr Top Microbiol Immunol 1996;211:269-78.
6. Benedetti L, Levin AA, Scicchitano BM, et al. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 1997;90:1175-85.
7. Melnick A, Ahmad KF, Arai S, et al. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Mol Cell Biol 2000;30:6550-67.
8. Melnick A, Carlile G, Ahmad KF, et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 2002;22:1804-18.
9. Puccetti E, Sennewald B, Fosca-Ferrara F, et al. Downstream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARα fusion protein with the histone-deacetylase recruiting co-repressor complex. Hematol J 2001;2:385-92.
10. Ahmad KF, Engel CK, Prive GG. Crystal structure of the BTB domain from PLZF. Proc Natl Acad Sci U S A 1998;95:12123-8.
11. Grignani F, Kinsella T, Mencarelli A, et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/ retroviral vector expressing the green fluorescence protein. Cancer Res 1998;58:14-9.
12. Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RARα) and PLZF-RARα fusion proteins on retinoic acid signalling. Mol Cell Biol 1997;17:4859-69.
13. Nervi C, Poindexter EC, Grignani F, et al. Characterization of the PML-RARα chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. Cancer Res 1992;52:3687-92.
14. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000;5:821-30.
15. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000;5:811-20.
16. Beissert T, Puccetti E, Bianchini A, et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003;102:2985-93.
17. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
18. Romanski A, Bacic B, Bug G, et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell tines of acute lymphoblastic leukemia. Haematologica 2004;89:419-26.
19. Remiszewski SW, Sambucetti LC, Bair KW, et al. N-hydroxy-3-phenyl-2- propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[(2-hydroxyethyl)[2-(1H- indol-3-yl)ethyl]aminolmethyl]phenyll-2-propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-24.
20. Dong S, Zhu J, Reid A, et al. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-α fusion protein. Proc Natl Acad Sci U S A 1996;93:3624-9.
21. Nagpal S, Priant S, Nakshatri H, Chambon P. RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993;12:2349-60.
22. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61:2-7.
23. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to HA in APL. Nat Genet 1998;18:126-35.
24. Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:9028-33.
25. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998;91:2634-42.